Duraent Biologicals Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
- Paid Up Capital ₹ 5.00 M
- Company Age 14 Year, 8 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth %
- Net Worth
- Total Assets %
About Duraent Biologicals
Duraent Biologicals Limited (DBL) is a Public Limited Indian Non-Government Company incorporated in India on 24 June 2010 and has a history of 14 years and eight months. Its registered office is in Chennai, Tamil Nadu, India.
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 5.00 M, as per Ministry of Corporate Affairs (MCA) records.
Sridevi, Arumugam Kavithadevi, and Bagavathy Subithakumar serve as directors at the Company.
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24100TN2010PLC076303
- Company No.
076303
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
24 Jun 2010
- Date of AGM
28 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Duraent Biologicals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sridevi  | Director | 01-Jul-2010 | Current |
| Arumugam Kavithadevi | Director | 01-Jul-2010 | Current |
| Bagavathy Subithakumar | Director | 24-Jun-2010 | Current |
Financial Performance of Duraent Biologicals.
Duraent Biologicals Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Duraent Biologicals?
In 2020, Duraent Biologicals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sea Monk Seafood LlpSridevi and Bagavathy Subithakumar are mutual person
- Duraent Lifesciences Llp
Sridevi is a mutual person
- Vigour Life Sciences Private Limited
Sridevi is a mutual person
- Sanum Sanguineas Solutions Private Limited
Sridevi is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Duraent Biologicals?
Unlock and access historical data on people associated with Duraent Biologicals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Duraent Biologicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Duraent Biologicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
